Teva Pharmaceutical Industries Limited develops, manufactures, and markets generic and human pharmaceuticals, as well as active pharmaceutical ingredients (APIs) in North America, Europe, Latin America, Asia, and Israel. It offers generic pharmaceutical products in various dosage forms, including tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company’s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease. Teva also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; and Cyclohaler, a single dose dry powder device. The company’s branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms linked to asthma or chronic obstructive pulmonary disease and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it manufactures and sells APIs for respiratory products, dermatological hormones, anti-inflammatories, oncolytics, immunosuppressants, and muscle relaxants, as well as custom-manufactured APIs for various proprietary drug manufacturers. Further, the company has projects in various clinical and pre-clinical development stages in the areas of psoriasis, asthma, amyotrophic lateral sclerosis, Crohn’s disease, lupus/lupus nephritis, and oncology. Additionally, Teva manufactures and markets proprietary, as well as generic veterinary pharmaceutical products under IVX Animal Health brand focusing on antimicrobials, antiparasitics, antipruritics and antiseborrheics, grooming aids, nutraceuticals, and otics. The company has strategic alliances with Impax Laboratories, Inc.; Lundbeck A/S; and Barr Pharmaceuticals, Inc. Teva Pharmaceutical was founded in 1901 and is headquartered in Petach Tikva, Israel.